Highlighting Deuruxolitinib for Alopecia Areata

Opinion Video Author(s): Panelists discuss how deuruxolitinib, evaluated in the THRIVE-AA1 and THRIVE-AA2 phase 3 trials, differs from previous Janus kinase (JAK) inhibitors in its formulation and efficacy, and why ensuring long-term patient adherence through 24 weeks is crucial for treatment durability and success. Video content above is prompted by the following: Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics. A Population Health Approach to Managing Heart Failure A Population Health Approach to Managing Heart Failure 2 Commerce DriveSuite 100Cranbury, NJ 08512 © 2025 MJH Life Sciences® and AJMC®. All rights reserved.